What are you looking for?

>Announcement >Your Guide to Joining in September!

Your Guide to Joining in September!

Everything you need to know about the 4th edition of The Antibody Series

Overview Details
  • In-person: 4 – 6 September, 2024
  • Location: Madeira Island, Portugal
  • Free on-demand: Register here
  • Chairman: Dr. Paul Parren, CSO at Gye


The Antibody Series is the fastest growing antibody conference of its kind. Started in 2021, in Porto, Portugal, the premier annual conference brings together international experts in the field of antibody discovery and development to discuss innovative topics and trends in the industry. Attendees benefit from knowledge exchange and opportunities to network with their peers in a scientifically stimulating environment, co-joined by +4,000 members online & on-demand.

Format & Attendance
  1. In-person: Attendance to The Antibody Series is via invitation only. Registration for in-person is closing shortly; If you have previously joined, please check your inbox and RSVP by June 30th.
  2. Free Online: The Antibody Series lectures will be made accessible & free to watch on-demand to anyone wishing to join us online. To register for the upcoming on-demand and Antibody Series 2024 portal access, register here.

If you have any questions about the conference, please contact us here.

Scientific Program
  1. View all speakers: www.antibodyseries.com/speakers
  2. View program sessions here: https://antibodyseries.com/program/#all-events

Wednesday 4th September:

Session: Antibodies in Close-up

Andrew Ward, Professor at the Scripps Research Institute: (Keynote) Deconstructing polyclonal antibody responses at the molecular level using cryoEM

Thomas Sharp, Associate Professor at the University of Bristol: Structural biology of complement initiation by the C1 complex

Thursday 5th September:

Session: Antibody Ensemble

George Georgiou, Dula D. Cockrell Centennial Chair and Professor at UT Austin: (Keynote) Understanding the Human Serological Antibody Repertoire

Rob de Jong, Director, Antibody Research and Technology at Genmab: Single molecule studies and applications of antibodies engineered to induce cell surface-restricted hexamerization

Matthew Romei, Senior Scientist, Dualitas Therapeutics, Inc: Antibody Architectures and Interfaces: Nature’s Guide to Biotherapeutic Engineering

Session: Antibody Protection

Dennis Burton, Chair and Professor in the Department of Immunology & Microbiology: How antibodies protect against viruses

Laura Walker, Head of Infectious Disease Biotherapeutic Discovery and Engineering at Moderna: mRNA-based delivery of engineered antibodies to combat SARS-CoV-2

Session: Computation and Design

Charlotte Deane, Professor of Structural Bioinformatics in the Department of Statistics at the University of Oxford: Moving the dial on computational antibody design

Jeffery Gray, Professor of Chemical and Biomolecular Engineering, Johns Hopkins University: Artificial Intelligence Tools for Antibody Engineering

Alex Lugovskoy, Co-founder and CEO of Diagonal Therapeutics: Computational epitope filtering of antibody repertoires enables reliable design of agonist antibodies to multimeric receptor complexes

Session: Scientific Briefings

Jannick Bendtsen, co-founder and CEO of PipeBio: An integrated bioinformatics platform for antibody discovery: Advancing data-driven decision making for therapeutic candidate selection

Speaker TBA: Lecture TBA

Friday 6th September

Session: New Targets and Technologies

Christoph Rader, CTO at Aethon Therapeutics: Creating and targeting synthetic neoepitopes on cancer cells

Marc Robillard, co-founder and CEO of Tagworks: Click-to-Release: on-target activation and off-target deactivation of antibody-based therapies

Sally Ward, Director of Translational Immunology at the Centre for Cancer Immunology in the University of Southampton: Targeting FcRn for the therapy of autoimmune disease

Mitchell Ho, Senior Investigator and Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the Center for Cancer Research: Engineering Immunotoxins and CAR-T Cells for Cancer Therapy Using Nanobodies

Joy Zuchero, Director and Principal Scientist at Denali Therapeutics: The Transport Vehicle: Engineering the Fc and Utilizing the Brain Vasculature to Deliver CNS Therapeutics

The Antibody Series 2024 Sponsors

Thank you to our supporting sponsors:


PipeBio, Thermo Fisher Scientific


Infors HT, Sphere Fluidics

We look forward to welcoming you to Madeira Island and welcoming our growing community online!

Register free for upcoming on-demand talks